Acumen posts $121.3M loss, cash burn accelerates before key Alzheimer's trial
Clinical-stage biotech reports $115.5M operating cash burn as it awaits late 2026 ALTITUDE-AD Phase 2 data
Acumen Pharmaceuticals reported a fiscal 2025 net loss of $121.3 million, or $2.00 per share, missing analyst estimates by a wide margin as the clinical-stage biotechnology company burned through $115.5 million in cash while awaiting crucial Alzheimer's disease trial results.
The Charlottesville, Virginia-based company, which has no product revenue and is developing treatments targeting amyloid beta oligomers in Alzheimer's disease, posted the loss for the year ended December 31, 2025. Analyst consensus had estimated a loss of $1.56 per share for the period, though some projections ranged as high as $0.68, representing a significant miss versus expectations.
Acumen's cash burn accelerated sharply from previous quarters, with net cash used in operating activities reaching $115.5 million. The company ended the year with $116.9 million in cash, cash equivalents, and marketable securities, providing a runway into early 2027.
To bolster its liquidity position, Acumen completed a $35.75 million private placement in March 2026, selling shares at $3.30 each. The financing was led by existing investor RA Capital Management, with participation from ADAR1 Capital Management, Sands Capital, and another large institutional investor.
"This financing from committed institutional investors strongly validates our portfolio and our Enhanced Brain Delivery strategy," said Daniel O'Connell, Acumen's chief executive officer, in the private placement announcement.
The proceeds are primarily intended to advance Acumen's Enhanced Brain Delivery program, which pairs an amyloid beta oligomer-targeting antibody with transferrin receptor targeting technology. The company aims to submit an Investigational New Drug application for a lead clinical candidate by mid-2027.
Investors are focused on Acumen's ALTITUDE-AD Phase 2 trial of sabirnetug (ACU193), an antibody treatment for early Alzheimer's disease. The company completed enrollment in the study in March 2025 and expects to report topline results in late 2026.
Analysts maintain a bullish outlook on the stock, with a Strong Buy consensus and an average price target of $7.20, according to market data. The six analysts covering the company all rate it a Buy, with no Hold or Sell ratings. However, the disconnect between analyst optimism and the company's deteriorating financial metrics highlights the binary nature of clinical-stage biotech investments.
Acumen's shares trade at a market capitalization of approximately $157 million, with the stock down about 27% from its 52-week high of $3.60. The stock has been volatile, trading in a range between $0.86 and $3.60 over the past year.
The company's focus on amyloid beta oligomers rather than plaques represents a different approach to Alzheimer's treatment than many failed therapies targeting beta-amyloid plaques. The ALTITUDE-AD Phase 2 trial is targeting patients with early Alzheimer's disease and mild cognitive impairment due to Alzheimer's.
With cash runway extending only into early 2027 and the next major clinical catalyst not arriving until late 2026, Acumen faces a challenging period. The private placement provides additional breathing room, but investors will be closely watching the ALTITUDE-AD results as the make-or-break moment for the company's lead program.